Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609520 | 0.91 | MAOA (0.50) | MAOBMAOACYP2A6CRBNRIPK1 | |
| SCHEMBL5429182 | 0.91 | MAOA (0.55) | MAOBMAOACYP2A6CRBNPTGIR | |
| SCHEMBL30939414 | 0.89 | MAOB (0.44) | MAOBMAOACYP2A6CRBNKDM1A | |
| SCHEMBL29850010 | 0.89 | MAOB (0.44) | MAOBMAOACYP2A6CRBNKDM1A | |
| SCHEMBL30892876 | 0.89 | MAOA (0.58) | MAOBMAOACYP2A6PTGIRSMN1; SMN2 | |
| SCHEMBL5215573 | 0.85 | MAOA (0.42) | MAOBMAOACYP2A6CRBNKDM1A | |
| SCHEMBL1939589 | 0.85 | MAOA (0.44) | MAOBMAOACYP2A6CRBNKDM1A | |
| SCHEMBL14081453 | 0.82 | CARM1 (0.43) | MAOBMAOASMN1; SMN2CARM1PRMT6 | |
| SCHEMBL25866081 | 0.82 | CARM1 (0.36) | MAOBMAOACRBNRIPK1CARM1 | |
| SCHEMBL24111487 | 0.79 | CYP2A6 (0.35) | MAOBMAOACYP2A6CRBNRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4694874-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC (KR) | 2025-12-04 | — | — | US | disclosed |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | Rubedo Life Sciences, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| US-20250243220-A1 | ATR INHIBITORS | APREA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1341761-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002030895-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP1, ENPP3, SMPD1 | MAOB 828/4885MAOA 724/4885CYP2A6 1837/4885 |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | MAOB 1194/4885MAOA 640/4885CYP2A6 436/4885 |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX4 | MAOB 990/4885MAOA 888/4885CYP2A6 1293/4885 |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | MAOB 901/4885MAOA 807/4885CYP2A6 1073/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | MAOB 1508/4885MAOA 1486/4885CYP2A6 2903/4885 |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | MAOB 1289/4885MAOA 1384/4885CYP2A6 2826/4885 |
| US-20250243220-A1 | ATR INHIBITORS | ATR, CHEK1, CHEK2 | MAOB 4196/4885MAOA 4622/4885CYP2A6 4373/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MAOB 81/4885MAOA 102/4885CYP2A6 40/4885 |
| US-20250270194-A1 | PYRAZOLE-SUBSTITUTED CYCLOPENTANOL ESTER DERIVATIVE AND USE THEREOF | CYP51A1, CYP11B2, CYP11B1 | MAOB 1834/4885MAOA 3007/4885CYP2A6 118/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | MAOB 2519/4885MAOA 2481/4885CYP2A6 3972/4885 |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | GPX4, GPX1, PRDX3 | MAOB 1289/4885MAOA 1384/4885CYP2A6 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.